58327-76-7

Usage

Uses

Used in Pharmaceutical Research and Development:
3-AMINO-4,6-DIMETHYLTHIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID is utilized as a key intermediate in the synthesis of novel drugs and medicinal compounds due to its unique structure and properties. It plays a crucial role in the development of pharmaceuticals with potential therapeutic applications across various medical fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-AMINO-4,6-DIMETHYLTHIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID is employed as a versatile building block for the creation of new chemical entities. Its incorporation into drug molecules can lead to the discovery of compounds with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
Used in Drug Discovery:
3-AMINO-4,6-DIMETHYLTHIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID is used as a starting material in drug discovery processes, where it can be modified and combined with other chemical moieties to generate new drug candidates. Its presence in these molecules can contribute to the development of therapeutic agents with novel mechanisms of action and potential applications in treating various diseases and conditions.
Used in Biochemical Research:
In biochemical research, 3-AMINO-4,6-DIMETHYLTHIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID serves as a valuable tool for studying the interactions between small molecules and biological targets. Its unique structural features allow researchers to probe the binding and activity of 3-AMINO-4,6-DIMETHYLTHIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID with various proteins, enzymes, and receptors, providing insights into its potential therapeutic effects and mechanisms of action.
Overall, 3-AMINO-4,6-DIMETHYLTHIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID is a versatile and valuable compound in the field of pharmaceuticals and medicinal chemistry, with a wide range of applications in drug development, research, and discovery. Its unique structural properties make it an essential component in the design and synthesis of novel therapeutic agents with potential applications in various medical areas.

InChI:InChI=1/C10H10N2O2S/c1-4-3-5(2)12-9-6(4)7(11)8(15-9)10(13)14/h3H,11H2,1-2H3,(H,13,14)

Upstream product

• 52505-56-3 ethyl 3-amino-4,6-dimethylthieno[2,3-b]pyridine-2-carboxylate 
• 54585-47-6 3-cyano-4,6-dimethyl-2-mercaptopyridine 
• 79-11-8 chloroacetic acid 
• 52505-44-9 methyl 3-amino-4,6-dimethylthieno[2,3-b]pyridine-2-carboxylate 
• 14237-71-9 2-chloro-4,6-dimethylnicotinonitrile 
• 128257-06-7 2-(3-Cyano-4,6-dimethyl)pyridyl (ethoxycarbonyl)methyl sulfide 
• 54585-47-6 4,6-Dimethyl-2-thioxo-1,2-dihydro-pyridine-3-carbonitrile 
• 55023-72-8 3-amino-4,6-dimethyl-thieno[2,3-b]pyridine-2-carboxylic acid; potassium salt 

Downstream Products

• 1610591-86-0 3-amino-N-(2-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)ethyl)-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide 
• 1610591-88-2 3-amino-N-(4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)butyl)-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide 
• 1610591-89-3 3-amino-N-(5-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)pentyl)-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide 
• 1610591-93-9 3-amino-N-(5-(4-(2,3-dichlorophenyl)piperazin-1-yl)pentyl)-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide 
• 58327-83-6 2-(4-chlorobenzylidene)-4,6-dimethyl-2,3-dihydrothieno[2,3-b]pyridin-3-one 
• 128918-11-6 3-Amino-4,6-dimethyl-thieno[2,3-b]pyridine-2-carboxylic acid cyclohexylamide 
• 128918-28-5 3-Amino-4,6-dimethylthieno<2,3-b>pyridine-2-carbohydrazide 
• 72701-64-5 3-Amino-4,6-dimethyl-thieno<2,3-b>pyridin-2-carbonsaeureanilid 
• 99504-81-1 3-(p-nitrobenzylideneamino)-2,7,9-trimethyl pyrido<3',2':4,5>thieno-<3,2-d>pyrimidin-4(3H)one 
• 115919-85-2 3-Amino-4,6-dimethyl-thieno<2,3-b>pyridin-2-carbonsaeure-4-nitro-phenylester 
• 55023-32-0 4,6-dimethylthieno[2,3-b]pyridine-3(2H)-one 

Relevant academic research and scientific papers

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D2 receptor

Biased agonism at GPCRs highlights the potential for the discovery and design of pathway-selective ligands and may confer therapeutic advantages to ligands targeting the dopamine D2 receptor (D2R). We investigated the determinants of efficacy, affinity, and bias for three privileged structures for the D2R, exploring changes to linker length and incorporation of a heterocyclic unit. Profiling the compounds in two signaling assays (cAMP and pERK1/2) allowed us to identify and quantify determinants of biased agonism at the D2R. Substitution on the phenylpiperazine privileged structures (2-methoxy vs 2,3-dichloro) influenced bias when the thienopyridine heterocycle was absent. Upon inclusion of the thienopyridine unit, the substitution pattern (4,6-dimethyl vs 5-chloro-6-methoxy-4-methyl) had a significant effect on bias that overruled the effect of the phenylpiperazine substitution pattern. This latter observation could be reconciled with an extended binding mode for these compounds, whereby the interaction of the heterocycle with a secondary binding pocket may engender bias.

Synthesis of some new pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4(3H)-ones and pyrido[3′,2′: 4,5]thieno[2,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives

2,3-Disubstituted-pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4( 3H) -ones 8a-8c, 9a-9c were obtained by treatment of pyrido[3′,2′:4,5]thieno[3,2-d][1,3]oxazin-4(3H)-one derivative 3, 3-diacetylamino-thieno[2,3-b]pyridine derivative 5 and 3-ethoxymethyleneaminothieno[2,3-b]pyridine derivative 7a with appropriate amines, respectively. Condensation of compounds 8b, 9b with appropriate α-chlorocarbonyl compounds gave the corresponding 3-substituted carbonylmethylene-pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4(3H)-one derivatives 13a-d. 3-N-Substituted-pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4(3H)-ones 15a,b, 16a,b and 18a,b were also obtained by cyclization of carbohydrazide 14 with different reagents under a variety of conditions. On the other hand, cyclization of 3-amino-4-imino-pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4(3H)-ones 21a,b with appropriate orthoesters afforded the corresponding 3,5-dialkyl-pyrido[3′,2′:4,5]thieno[2,3-e]-1,2,4-triazolo[1,5-c] pyrimidines 22a-f.